Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-12-20
2008-03-04
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S351000, C435S069700
Reexamination Certificate
active
07338930
ABSTRACT:
Methods for regulating levels of nitric oxide are disclosed. The methods utilize IL-17 receptors, which may be used in conjunction with inhibitor of IL-1 and/or TNF.
REFERENCES:
patent: 5869286 (1999-02-01), Yao et al.
patent: 6406867 (2002-06-01), Yu et al.
patent: 6680057 (2004-01-01), Yao et al.
patent: WO 96/29408 (1996-09-01), None
Aarvak et al., “Analysis of IL-17 and other cytokines and surface markers of RA inflammatory T Cell clones,”American College of Rheumatology(ACR) meeting, Poster 1448, Nov. 1997.
Amin, A. R. et al., “The expression and regulation of nitric oxide synthase in human osteroarthritis-affected chondrocytes: Evidence for up-regulated neuronal nitric oxide synthase,”J. Exp. Med., 182:2097-2102, Dec. 1995.
Ankarcrona, M. et al., “Interleukin-1 beta-induced nitric oxide production activates apoptosis in pa creatic RINm5F cells,”Exp. Cell. Res., 213(1):172-177, 1994.
Attur, M. G,. et al., “Interleukn-17 up-regulation of nitric oxide production in human osteoarthritis cartilage,”Arthritis&Rheumatism, 40(6):1050-1053, 1997.
Baragi, V. M. et al., “Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation,”J. Clin. Invest, 96(5):2454-2460, 1995.
Caron, J. P. et al., “Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis,”Arthritis&Rheumatism, 39(9):1535-1544, 1996.
Chabaud et al., “Regulation of the effects of IL 17 on IL 6 and LIF production by RA synoviocytes,”American College of Rheumatology(ACR) meeting, Poster 1449, Nov. 1997.
Dudler et al., “In vivo effects of murine recombinant interleukin-17 on synovial joint in mice,”American College of Rheumatology(ACR) meeting, Poster 1450, Nov. 1997.
Fossiez et al., “T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoetic cytokines,”J. Exp. Med., 183:2593-2603, 1996.
Fouilhoux et al., “Production of IL-17 and its regulation in rheumatoid synovium,”American College of Rheumatology(ACR)meeting, Poster 1447, 1997.
Jovanovic, et al., “IL-17 stimulates the secretion of proinflammatory cytokines by human macrophages,”American College of Rheumatology(ACR) meeting, Poster 1446, Nov. 1997.
Liew, F. Y., “Nitric oxide in infectious and autoimmune diseases,”CIBA Foundation Symposium, 195:234-244, 1995.
Lotz et al., IL-17 promotes cartilage degradation,Arthritis and Rheumatism, 39 supp. (9):S120, No. 559, 1996.
Spriggs, M. K., “Interleukin-17 and its receptor,”J. Clin. Immunol., 17(5):366-369, 1997.
Yao et al., “Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor,”Immunity 3:811-821, 1995.
Yao et al., “Complete nucleotide sequence of the mouseCTLA8gene,”Gene, 168:223-225 1996.
Yao et al., “Human IL-17: A novel cytokine derived from T cells,”J. Immunol., 155:5483-5486, 1995.
Immunex Corporation
Jiang Dong
Klaniecki James E.
Spector Lorraine
LandOfFree
Methods of treating osteoarthritis using IL-17 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating osteoarthritis using IL-17 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating osteoarthritis using IL-17 receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3977943